Evolus announces acceptance of FDA BLA resubmission for prabotulinumtoxinA

Evolus announced the acceptance of its resubmission of its biologics license application, or BLA, for its lead product candidate, prabotulinumtoxinA, by the FDA. The FDA considered the resubmission a Class 2 response and has assigned a February 2, 2019 action date per the Prescription Drug User Fee Act.
https://bit.ly/2PlA14n